BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned an average rating of “Hold” from the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $9.14.

Several research firms recently commented on BCRX. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. Royal Bank of Canada raised BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Tuesday, January 2nd. Finally, Barclays started coverage on BioCryst Pharmaceuticals in a report on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price target for the company.

In other news, CMO William P. Sheridan sold 64,310 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, November 13th. The stock was sold at an average price of $4.72, for a total value of $303,543.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers grew its stake in shares of BioCryst Pharmaceuticals by 7.8% during the second quarter. Rhumbline Advisers now owns 94,303 shares of the biotechnology company’s stock worth $524,000 after purchasing an additional 6,835 shares during the period. Bank of New York Mellon Corp grew its stake in shares of BioCryst Pharmaceuticals by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 369,561 shares of the biotechnology company’s stock worth $2,055,000 after purchasing an additional 8,272 shares during the period. Legal & General Group Plc grew its stake in shares of BioCryst Pharmaceuticals by 4.9% during the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares during the period. Teachers Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 55.9% during the second quarter. Teachers Advisors LLC now owns 196,385 shares of the biotechnology company’s stock worth $1,092,000 after purchasing an additional 70,438 shares during the period. Finally, TIAA CREF Investment Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 33.2% during the second quarter. TIAA CREF Investment Management LLC now owns 468,882 shares of the biotechnology company’s stock worth $2,607,000 after purchasing an additional 116,782 shares during the period. 84.82% of the stock is owned by institutional investors.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) traded down $0.09 during mid-day trading on Tuesday, hitting $4.51. The company’s stock had a trading volume of 916,901 shares, compared to its average volume of 1,456,138. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. The company has a market cap of $444.79, a P/E ratio of -7.06 and a beta of 3.05. BioCryst Pharmaceuticals has a 52 week low of $3.95 and a 52 week high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.18). The business had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. BioCryst Pharmaceuticals’s revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.16) EPS. equities analysts expect that BioCryst Pharmaceuticals will post -0.71 EPS for the current year.

TRADEMARK VIOLATION WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of “Hold” by Brokerages” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/30/biocryst-pharmaceuticals-inc-bcrx-given-consensus-recommendation-of-hold-by-brokerages-3.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply